Insights from 2024 ESGO Annual Meeting
ESGO 2024 Insights: "COPELIA Trial - Cediranib With Weekly Paclitaxel or Olaparib vs. Weekly Paclitaxel Chemo for Advanced/Recurrent Endometrial Cancer"
By
Insights from 2024 ESGO Annual Meeting
FEATURING
Andrew Clamp
By
Insights from 2024 ESGO Annual Meeting
FEATURING
Andrew Clamp
Comments 0
Login to view comments.
Click here to Login